Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism.
10.7534/j.issn.1009-2137.2014.03.056
- Author:
Jin-Shu SHI
1
,
2
;
Juan ZHANG
1
;
Jian LI
3
Author Information
1. Department of Hematology, The Second Hospital Affliated to Nanchang Universitor, Jiangxi Provincial Key Laboratory of Blood Deseases
2. Postgraduate School, Medical Department, Nanchang University, Nanchang 330006, Jiangxi Province, China.
3. Department of Hematology, The Second Hospital Affliated to Nanchang Universitor, Jiangxi Provincial Key Laboratory of Blood Deseases. E-mail:jeniferjian@gmail.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse;
genetics;
metabolism;
MicroRNAs;
metabolism;
Signal Transduction
- From:
Journal of Experimental Hematology
2014;22(3):869-872
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin's lymphoma (NHL), account for 30%-40% of NHL in adults, the 5-year survival rate is approximately 25%. Although there was a standard treatment to DLBCL today, approximately 50% of patients can not be cured. As a result, it is still a diligent direction of the researchers to understand the pathogenesis of DLBCL and to explore new effective treatment. Recently, the study of microRNA is a hot topic in biology, microRNAs are a class of small non-coding RNA that have emerged to regulate various of biological processes. MiR-155 is one of the most well-known oncogenic micro-RNA, miR-155 overexpression has been documented in a number of lymphoid neoplasms, extraordinarily in DLBCL. MiR-155 can promote the occurrence of lymphoma through various signaling pathways, such as the BMP/TGF-β and RhoA pathway, it is expected to become a new target for treatment of DLBCL. This article reviews the role and possible mechanisms of miR-155 in the pathogenesis of DLBCL.
